Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
•
Primary Care
Can a patient with a PMHx of pancreatic injury or disease (i.e. blunt trauma, recurrent pancreatitis) take a GLP-1 agonist safely in the setting of morbid obesity and type 2 diabetes?
Related Questions
How do you approach managing patients with diabetic kidney disease and proteinuria who develop hypoglycemia after initiation of a SGLT2 inhibitor?
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
After what time frame off GLP-1 RA therapy should you restart at the lowest starting dose?
What is the typical timeline for remission of autoimmune hypoglycemia?
What is the preferred first-line non-insulin agent in patients with ketosis-prone diabetes during "remission" and evidence of preserved beta cell function?
What is the recommended frequency and duration of exercise bouts in order to sustain the beneficial effects of exercise on insulin sensitivity?
Do you routinely monitor INR when starting GLP1 R agonist therapy on patients taking warfarin?
Would you recommend statin initiation in a young adult patient (age < 40) with type 1 diabetes mellitus and LDL cholesterol levels greater than 100 without any cardiovascular risk factors?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
Is GLP-1 therapy a viable treatment option for a patient with Type 2 Diabetes complicated by atherosclerotic heart disease and cholelithiasis?
